Fans don't think that the two colors in the Super Bowl 2025 logo — red and green — are a coincidence Skyler Caruso is a Writer and Reporter of PEOPLE Digital Entertainment. She joined PEOPLE ...

Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA ...

Currently, SAGE has two FDA-approved drugs with Zulresso and Zurzuvae, and both were developed for PPD. However, Zulresso was discontinued last December, which is why SAGE doubled down on Zurzuvae.

Sage Therapeutics has clarified that there is no definitive timeline set for the review process and no decisions have been made regarding potential strategic alternatives at this stage. The ...

Sage already has one drug on the market in Zulresso (brexanolone), an intravenously-administered drug for postpartum depression (PPD), but sales of that are small at around $1.5 million per ...

Towards the end of last year, Sage also announced sweeping job losses and a cut in its R&D programmes to reduce costs, and also decided to discontinue older PPD therapy Zulresso (brexanolone ...